|
|
Tên thương mại |
|
|
Các tên thương mại được cung cấp và thành phần tá dược có thể khác nhau giữa các quốc gia và các hãng dược
|
Bileco |
Argentina |
Blemisin |
Thổ Nhĩ Kỳ |
Blenamax |
Colombia, Malaysia, Úc |
Blenoxane |
Hoa Kỳ, Úc |
Bleo-Kyowa |
Anh |
Bleocell |
Đức |
Bleocin |
Ả Rập Saudi, Ba Lan, Bồ Đào Nha, Hungary, Hy Lạp, Malaysia, Nhật, Peru, Thổ Nhĩ Kỳ, United Arab Emirates |
Bleocip |
Ả Rập, Venezuela |
Bleocris |
Argentina, Chile, Peru |
Bleolem |
Colombia, Mexico |
Bleomax |
Mexico |
Bleomedac |
Đức |
Bleomicina |
Chile, Colombia, Ecuador, Mexico, Peru, Tây Ban Nha, Ý |
Bleomycin |
Anh, Áo, Ba Lan, Hà Lan, Hoa Kỳ, Hungary, Iceland, Iran, Na Uy, Phần Lan, Romania, Thụy Điển, Úc, Đan Mạch, Đức |
Bleomycine |
Bỉ, Canada, Ireland, Luxembourg, Malaysia, Morocco, new zealand, Pháp, Thụy Sỹ, Tunisia |
Bleomycine A |
Đan Mạch |
Bleomycinum |
Đức |
Bleozen |
Peru |
Blexit |
Chile |
Blocamicina |
Argentina |
Bloicin |
Ả Rập, Peru |
Blomindex |
Mexico |
Blucin |
Morocco |
DBL Bleomycin |
Malaysia, new zealand |
Ifabec |
Mexico |
Lyoble |
Peru |
Nikableocina |
Chile |
Oncobleocin |
Colombia |
|
|
|
|
Tài liệu tham khảo : Bleomycin sulfate |
|
|
Loại |
Nguồn |
3 |
Tạp chí |
Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
81 |
Tạp chí |
Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678. |
84 |
Tạp chí |
Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499. |
99 |
Tạp chí |
Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
169 |
Tạp chí |
Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363. |
182 |
Tạp chí |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60. |
244 |
Tạp chí |
Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913. |
248 |
Tạp chí |
Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304. |
249 |
Tạp chí |
Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
251 |
Tạp chí |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
252 |
Tạp chí |
Koberda M, Zieske PA, Raghavan NV, Payton RJ. Stability of bleomycin sulfate reconstituted in 5% dextrose injection or 0.9% sodium chloride injection stored in glass vials or polyvinyl chloride containers. Am J Hosp Pharm 1990 ; 47: 2528-2529. |
307 |
Tạp chí |
Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799. |
334 |
Tạp chí |
Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992. |
335 |
Tạp chí |
Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406. |
492 |
Tạp chí |
Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189. |
905 |
Tạp chí |
Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017. |
1410 |
Tạp chí |
Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145. |
1423 |
Tạp chí |
Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518. |
3128 |
Thông tin của nhà sản xuất |
Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013 |
3420 |
Tạp chí |
El Kateb N, Chaussard M, Bellenger P, Petit A, Faure P. Stability of an extemporaneously prepared bleomycin-lidocaine-epinephrine intradermal admixture used in dermatology J Oncol Pharm Practice 2014 ; 21, 3: 178-187. |
3578 |
Thông tin của nhà sản xuất |
Cisplatin - Summary of Product Characteristics Accord Healthcare 2011 |
3644 |
Thông tin của nhà sản xuất |
Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010 |
3646 |
Thông tin của nhà sản xuất |
Bléomycine sulfate (Bléomycine Bellon®) - Résumé des caractéristiques du produit Sanofi Aventis France 2013 |
4154 |
Thông tin của nhà sản xuất |
Bleomycin sulfate- Summary of Product Characteristics Accord Health Care 2018 |
4471 |
Thông tin của nhà sản xuất |
Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019 Kyowa Kirin Pharma 2019 |
|
|